The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 12.Single-Agent Vs Combination Regimens

EP: 13.The Potential Impact of Investigational Therapies

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer

Now Viewing

EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer

EP: 17.Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays

EP: 18.The Effect of Adverse Event Profiles on Treatment Decisions

EP: 19.Evaluating Long-Term Safety Considerations for Targeted Therapies in Ovarian Cancer

Video content is prompted by the following:

Optimizing multidisciplinary collaboration between oncologists, gynecologic oncologists, and pathologists requires comprehensive knowledge sharing across specialties. Medical and gynecologic oncologists must understand available targeted therapies, biomarker requirements, and FDA or National Comprehensive Cancer Network guideline indications for ovarian cancer treatment. Equally important is understanding biomarker testing methodologies and interpretation criteria that determine treatment eligibility. Pathologists need detailed knowledge of biomarker interpretation schemes, as different cancer types have varying guidelines for markers like HER2, with separate interpretation standards for endometrial, gastric, and breast cancers affecting ovarian cancer treatment decisions.

Effective communication between oncologists and pathologists ensures accurate biomarker interpretation and optimal patient selection for targeted therapies. The complexity of biomarker scoring systems requires careful coordination, as demonstrated by the initial failure of mirvetuximab vedotin trials due to incorrect folate receptor α scoring mechanisms. Once refined scoring methods were implemented, the drug showed significant efficacy, highlighting the critical importance of using appropriate assessment algorithms. This collaboration extends to emerging biomarkers including B7-H4, TROP2, and mesothelin, where expression level requirements and optimal patient selection criteria are still being established.

Future challenges in multidisciplinary ovarian cancer care involve managing multiple antibody-drug conjugate options with similar payloads but different targets. As more targeted therapies become available, teams must determine optimal treatment sequencing when patients may be candidates for multiple biomarker-driven therapies. The decision between folate receptor α–targeting drugs with different payloads, or choosing between HER2 and folate receptor α–targeting approaches, requires ongoing collaboration and evidence-based decision-making. This evolving landscape demands continuous communication and updated protocols to ensure patients receive the most appropriate targeted therapy for their specific tumor characteristics.